Core Insights - The board of Ark Health (06086.HK) noted a recent increase in the company's share price on September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model as a cornerstone for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - Strategic partnerships were established with Innovent Biologics and Otsuka Pharmaceutical to integrate digital health solutions and improve patient outcomes in the growing weight management market in China [1] Summary by Categories - **Share Price Movement** - The board observed a rise in the company's share price on September 12, 2025 [1] - **Product Development** - The company launched the "Xing Shi" large model, which serves as the foundation for five key applications: AI Drug Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search [1] - **Strategic Partnerships** - A partnership with Innovent Biologics was formed to integrate Ark's digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital support [1] - Collaboration with Otsuka Pharmaceutical aims to combine AI technology with Otsuka's innovative drug portfolio to develop comprehensive digital solutions for drug support services and health education programs [1]